Clinical Trial

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 13, 2023 (before its estimated September 15, 2023 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II, non-randomized, open-label, multi-center study to evaluate the efficacy of neoadjuvant Sintilimab (PD-1 antibody) or combined with chemotherapy as first-line treatment in patients with stage III non-small cell lung cancer (NSCLC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-01-25; most recent amendment 2023-09-10.
Status change: Not Yet Recruiting → Recruiting 2023-09-10
Trial Details
NCT Number NCT04728724
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions Non-small Cell Lung Cancer Stage III
Enrollment 100 participants
Start Date 2022-09-10
Primary Completion 2023-09-15 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-13